NCT06728150View on ClinicalTrials.gov

Study Investigating the Role of Routine Screening and Molecular Characterisation of Brain Metastasis in the Management of High-risk Metastatic Breast Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Breast Cancer MetastaticBrain Metastasases
Interventions
RADIATION

computerized tomography

The patients will have 3 monthly CT scans of the brain for 2 years and 6 monthly CT scans for 2 years for total of 4 years.

Trial Locations (1)

Unknown

The Alfred, Melbourne

All Listed Sponsors
collaborator

The Alfred

OTHER

collaborator

Breast Cancer Trials, Australia and New Zealand

OTHER

lead

Monash University

OTHER

NCT06728150 - Study Investigating the Role of Routine Screening and Molecular Characterisation of Brain Metastasis in the Management of High-risk Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter